Description General description A highly potent, reversible, and selective inhibitor of cyclin-dependent kinases 1 and 5 (IC50 = 5 nM for CDK1; IC50 = 7 nM for CDK5). Reported to act by competing with ATP for binding to the catalytic site of the kinase. Also acts as a potent inhibitor of glycogen synthase kinase-3β (GSK-3β; IC50 = 80 nM). A potent, reversible, and selective inhibitor of Cdk1 (IC50 = 5 nM) and Cdk5 (IC50 = 7 nM) and glycogen synthase kinase-3β (GSK-3β; IC50 = 80 nM). The inhibition is competitive with respect to ATP. Packaging 1 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: no Primary Target CDK1 Product competes with ATP. Reversible: yes Target IC50: 5 nM, 7 nM, 80 nM, against Cdk1, Cdk5, and glycogen synthase kinase-3β (GSK-3β), respectively Packaging Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 4 months at -20°C. Other Notes Leclerc, S., et al. 2001. J. Biol. Chem.276, 251.